Compare BridgeBio Pharma Inc (BBIO) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Under Armour Inc Class A — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Under Armour Inc Class A trades at $5.36 (market cap $2.57B). The key difference: BridgeBio Pharma Inc is far larger — about 6.5× Under Armour Inc Class A's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| BBIO | UAA | |
|---|---|---|
Market Cap | $16.61B | $2.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $8.14 |
52-Week Low | $47.29 | $4.17 |
Enterprise Value | $18.16B | $3.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Under Armour (UAA) trades at $6.11, down 4.38% today, reflecting ongoing challenges. The stock shows a bearish technical trend with key support at $6. Recent Q2 2026 earnings beat expectations with EPS of $0.05 versus $0.02, but revenue declined year-over-year. Financials reveal negative net income margin of -9.98% and weak cash flow, with net cash outflow of $361.87 million in 2025. Analysts maintain a cautious stance amid soft demand in key markets.
The outlook remains challenging due to persistent revenue declines and profitability issues. Investment opportunities hinge on successful execution of turnaround strategies, but risks include intense competition and macroeconomic pressures. With a consensus price target of $5.96 below the current price, Wall Street sentiment is neutral to bearish, emphasizing the need for improved fundamentals to drive recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
